These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 35050728)

  • 1. No Evidence of Increased Risk of Breast Cancer in Women With Lynch Syndrome Identified by Multigene Panel Testing.
    Stoll J; Rosenthal E; Cummings S; Willmott J; Bernhisel R; Kupfer SS
    JCO Precis Oncol; 2020 Nov; 4():51-60. PubMed ID: 35050728
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multigene Panel Testing Provides a New Perspective on Lynch Syndrome.
    Espenschied CR; LaDuca H; Li S; McFarland R; Gau CL; Hampel H
    J Clin Oncol; 2017 Aug; 35(22):2568-2575. PubMed ID: 28514183
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevalence of Lynch syndrome in women with mismatch repair-deficient ovarian cancer.
    Hodan R; Kingham K; Cotter K; Folkins AK; Kurian AW; Ford JM; Longacre T
    Cancer Med; 2021 Feb; 10(3):1012-1017. PubMed ID: 33369189
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lessons learnt from implementation of a Lynch syndrome screening program for patients with gynaecological malignancy.
    Najdawi F; Crook A; Maidens J; McEvoy C; Fellowes A; Pickett J; Ho M; Nevell D; McIlroy K; Sheen A; Sioson L; Ahadi M; Turchini J; Clarkson A; Hogg R; Valmadre S; Gard G; Dooley SJ; Scott RJ; Fox SB; Field M; Gill AJ
    Pathology; 2017 Aug; 49(5):457-464. PubMed ID: 28669579
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Germline multigene panel testing of patients with endometrial cancer.
    Kral J; Jelinkova S; Zemankova P; Vocka M; Borecka M; Cerna L; Cerna M; Dostalek L; Duskova P; Foretova L; Havranek O; Horackova K; Hovhannisyan M; Chvojka S; Kalousova M; Kosarova M; Koudova M; Krutilkova V; Machackova E; Nehasil P; Novotny J; Otahalova B; Puchmajerova A; Safarikova M; Slama J; Stranecky V; Subrt I; Tavandzis S; Zikan M; Zima T; Soukupova J; Kleiblova P; Kleibl Z; Janatova M
    Oncol Lett; 2023 Jun; 25(6):216. PubMed ID: 37153042
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel deleterious c.2656G>T MSH2 germline mutation in a Pakistani family with a phenotypic overlap of hereditary breast and ovarian cancer and Lynch syndrome.
    Rashid MU; Naeemi H; Muhammad N; Loya A; Yusuf MA; Lubiński J; Jakubowska A; Hamann U
    Hered Cancer Clin Pract; 2016; 14():14. PubMed ID: 27413415
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of Lynch Syndrome in Patients with Endometrial Cancer Based on a Germline Next Generation Sequencing Multigene Panel Test.
    Kim YN; Kim MK; Lee YJ; Lee Y; Sohn JY; Lee JY; Choi MC; Kim M; Jung SG; Joo WD; Lee C
    Cancers (Basel); 2022 Jul; 14(14):. PubMed ID: 35884469
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Universal screening for Lynch syndrome in endometrial cancers: frequency of germline mutations and identification of patients with Lynch-like syndrome.
    Dillon JL; Gonzalez JL; DeMars L; Bloch KJ; Tafe LJ
    Hum Pathol; 2017 Dec; 70():121-128. PubMed ID: 29107668
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risks of colorectal and other cancers after endometrial cancer for women with Lynch syndrome.
    Win AK; Lindor NM; Winship I; Tucker KM; Buchanan DD; Young JP; Rosty C; Leggett B; Giles GG; Goldblatt J; Macrae FA; Parry S; Kalady MF; Baron JA; Ahnen DJ; Marchand LL; Gallinger S; Haile RW; Newcomb PA; Hopper JL; Jenkins MA
    J Natl Cancer Inst; 2013 Feb; 105(4):274-9. PubMed ID: 23385444
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Expression and clinical significance of MMR protein and MLH1 promoter methylation testing in endometrial cancer].
    Jin W; Wang LQ; Liu Y; Liu AJ
    Zhonghua Fu Chan Ke Za Zhi; 2018 Dec; 53(12):823-830. PubMed ID: 30585020
    [No Abstract]   [Full Text] [Related]  

  • 11. Somatic mismatch repair testing in evaluation of Lynch syndrome: The gap between preferred and current practices.
    Williams D; Vilar E; Shakrukh Hashmi S; Choates M; Noblin S; Mork M
    J Genet Couns; 2020 Oct; 29(5):728-736. PubMed ID: 31896172
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel variants of unknown significance in the
    Liccardo R; Della Ragione C; Mitilini N; De Rosa M; Izzo P; Duraturo F
    Cancer Manag Res; 2019; 11():6719-6725. PubMed ID: 31410062
    [No Abstract]   [Full Text] [Related]  

  • 13. Prevalence of mutations in BRCA and MMR genes in patients affected with hereditary endometrial cancer.
    Vietri MT; D'Elia G; Caliendo G; Casamassimi A; Federico A; Passariello L; Cioffi M; Molinari AM
    Med Oncol; 2021 Jan; 38(2):13. PubMed ID: 33484353
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Isolated Loss of PMS2 Immunohistochemical Expression is Frequently Caused by Heterogenous MLH1 Promoter Hypermethylation in Lynch Syndrome Screening for Endometrial Cancer Patients.
    Kato A; Sato N; Sugawara T; Takahashi K; Kito M; Makino K; Sato T; Shimizu D; Shirasawa H; Miura H; Sato W; Kumazawa Y; Sato A; Kumagai J; Terada Y
    Am J Surg Pathol; 2016 Jun; 40(6):770-6. PubMed ID: 26848797
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of tumor morphology with mismatch-repair protein status in older endometrial cancer patients: implications for universal versus selective screening strategies for Lynch syndrome.
    Rabban JT; Calkins SM; Karnezis AN; Grenert JP; Blanco A; Crawford B; Chen LM
    Am J Surg Pathol; 2014 Jun; 38(6):793-800. PubMed ID: 24503759
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risks of primary extracolonic cancers following colorectal cancer in lynch syndrome.
    Win AK; Lindor NM; Young JP; Macrae FA; Young GP; Williamson E; Parry S; Goldblatt J; Lipton L; Winship I; Leggett B; Tucker KM; Giles GG; Buchanan DD; Clendenning M; Rosty C; Arnold J; Levine AJ; Haile RW; Gallinger S; Le Marchand L; Newcomb PA; Hopper JL; Jenkins MA
    J Natl Cancer Inst; 2012 Sep; 104(18):1363-72. PubMed ID: 22933731
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risks of less common cancers in proven mutation carriers with lynch syndrome.
    Engel C; Loeffler M; Steinke V; Rahner N; Holinski-Feder E; Dietmaier W; Schackert HK; Goergens H; von Knebel Doeberitz M; Goecke TO; Schmiegel W; Buettner R; Moeslein G; Letteboer TG; Gómez García E; Hes FJ; Hoogerbrugge N; Menko FH; van Os TA; Sijmons RH; Wagner A; Kluijt I; Propping P; Vasen HF
    J Clin Oncol; 2012 Dec; 30(35):4409-15. PubMed ID: 23091106
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Management of ovarian and breast cancer risk in non-BRCA HBOC pathogenic variant carriers in a large California health care system.
    Powell CB; Laurent C; Garcia C; Hoodfar E; Karlea A; Kobelka C; Lee J; Roh J; Kushi LH
    Gynecol Oncol; 2022 Dec; 167(3):467-475. PubMed ID: 36220669
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Endometrial cancer in Lynch syndrome.
    Zhao S; Chen L; Zang Y; Liu W; Liu S; Teng F; Xue F; Wang Y
    Int J Cancer; 2022 Jan; 150(1):7-17. PubMed ID: 34398969
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lynch Syndrome in Thai Endometrial Cancer Patients.
    Manchana T; Ariyasriwatana C; Triratanachat S; Phowthongkum P
    Asian Pac J Cancer Prev; 2021 May; 22(5):1477-1483. PubMed ID: 34048176
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.